Cipla Ltd. — Regulatory Filings 2023

Oct 26, 2023

==> picture [84 x 30] intentionally omitted <==

26[th] October 2023

(1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA EQ

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Dear Sir/Madam,

Sub: USFDA inspection at InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility unit 1 and 2 of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the Company) located in Hauppauge, Long Island, New York, USA from 16[th] October 2023 to 25[th] October 2023.

The inspection concluded with zero Form 483 observations.

Please take the above information on record.

Yours faithfully,

For Cipla Limited

RAJENDR Digitally signed by RAJENDRA A KUMAR KUMAR CHOPRA Date: 2023.10.26 CHOPRA 14:12:40 +05'30' Rajendra Chopra Company Secretary

Prepared by: Muskan Jain

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Numbe r L24239MH1935PLC002380